Enter multiple symbols separated by commas

Stocks Bristol-Myers Squibb Co


  • This stock is no longer in the Top 20 most held Friday, 29 May 2015 | 11:51 AM ET
    Traders work on the floor of the New York Stock Exchange.

    New data provided to CNBC from eVestment shows the most popular stocks held by institutional funds.

  • Your first trade for Wednesday Tuesday, 26 May 2015 | 6:23 PM ET

    The "Fast Money" traders give their final trades of the day.

  • May 22- EU Medicines Agency:. *EU Medicines Agency recommendations for May 2015. *Recommends approval of cholesterol drug Repatha from Amgen Inc.

  • Lightning Round: This bargain stock goes to $100 Friday, 15 May 2015 | 7:33 PM ET
    Mad Money Lightning Round

    Are you ready skeedaddy???!!! It's time for the Lightning Round. Cramer makes the call on viewer favorites.

  • Investors were waiting for news that could move share prices from many bigger companies including Bristol-Meyers Squibb Co, Amgen Inc and Celgene Corp. Hot topics at the American Society of Clinical Oncology conference in Chicago will include immuno oncology and CAR-T cell therapies. Shares in Juno Therapeutics Inc, Kite Pharma Inc, BlueBird Bio Inc and...

  • Biotech investors: These are the key names to know Wednesday, 13 May 2015 | 11:53 AM ET

    Ahead of the world's biggest cancer research conference, the American Society of Clinical Oncology meeting, here are the companies to watch.

  • Spending on this type of meds hit a new milestone Tuesday, 5 May 2015 | 12:01 AM ET
    Employees walk past a Merck sign in front of the company's building in Summit, New Jersey.

    That's up more than 10 percent from 2013 and up from $75 billion five years earlier, according to a new report.

  • U.S. top court rejects hepatitis B drug patent case Monday, 4 May 2015 | 9:40 AM ET

    WASHINGTON, May 4- The U.S. Supreme Court on Monday brought to an end Bristol-Myers Squibb Co's attempt to revive patent protection for its Baraclude treatment for hepatitis B. The high court declined to hear Bristol-Myers' challenge to an appeals court ruling in favor of generic rival Teva Pharmaceutical Industries Ltd, which had successfully challenged the...

  • April 29- Pharmacy benefit manager Express Scripts Holding Co, which has aggressively negotiated lower costs of new hepatitis C drugs, on Wednesday said a new "focus area" will be subduing costs of a growing wave of pricey biotech cancer drugs. "This is going to be a much slower and much bigger effort over time than what you saw for hepatitis," Steve Miller, chief...

  • Janet Yellen

    U.S. stock index futures indicated a flat open on Tuesday ahead of the two-day FOMC meeting, housing data and a busy day of earnings.

  • April 28- Merck& Co's shares jumped almost 5 percent after the U.S. drugmaker reported better-than-expected quarterly results and released favorable data late Monday about the safety of its Januvia diabetes drug. The second-largest U.S. drugmaker on Tuesday said it earned $953 million, or 33 cents per share, in the first quarter. That compared with $1.71...

  • Early movers: BP, F, AAPL, BMY, COH, PFE & more Tuesday, 28 Apr 2015 | 8:01 AM ET
    A trader works on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • *FDA cites concerns over late-stage study design, results. April 27- U.S. Food and Drug Administration staff reviewers said an accelerated review of drugmaker Amgen Inc's skin cancer immunotherapy cannot be considered at this time, citing concerns over the design and results of a key study. T-Vec represents a new class of agent for the treatment of metastatic...

  • April 27- Drug developer Celladon Corp said it expected to announce lay-offs and cost cuts as its stock plunged to an all-time low after the company's lead experimental gene therapy to treat heart failure failed a key trial. Celladon lost nearly 80 percent of its market value in early trading on Monday, with the stock falling to a record low of $2.76.

  • *Celladon trial failure shows field remains high-risk. LONDON, April 27- GlaxoSmithKline is close to seeking European approval for a gene therapy drug to fight the immune deficiency disorder known as "bubble boy" disease, in the latest sign of a renaissance in the technology to fix faulty genes. Gene therapy last year won $3.0 billion of financing, up 510 percent on...

  • Why the S&P could break out this week Monday, 27 Apr 2015 | 7:12 AM ET
    Traders work on the floor of the New York Stock Exchange.

    As the Fed meets and earnings news rains down, the big question in the week ahead is whether the S&P 500 can manage a break out.

  • Bulls sniffing out an S&P breakout Monday, 27 Apr 2015 | 6:00 AM ET
    Traders work on the floor of the New York Stock Exchange.

    As the Fed meets and earnings news rains down, the big question in the week ahead is whether the S&P 500 can manage a break out.

  • April 25- Bristol-Myers Squibb Co said its experimental drug cured hepatitis C in over 90 percent of patients in combination with Gilead Sciences Inc's Sovaldi and a commonly prescribed drug, ribavirin, in a late-stage study. Bristol-Myers has been testing the drug, daclatasvir, in combination with Sovaldi after shelving plans to market another hepatitis C...

  • Cramer game plan: Countdown to Apple—play it right Friday, 24 Apr 2015 | 6:11 PM ET
    Apple Inc.

    Jim Cramer has a method to his madness when it comes to playing Apple. He gives his game plan for the big earnings report.

  • NEW YORK, April 24- Healthcare companies on a seven-year tear have been top performers so far in 2015, helping to push broad stock indexes to record levels, but traders are now looking to protect themselves from a selloff as they await major earnings reports in the sector. Companies reporting first-quarter earnings next week include Bristol-Meyers Squibb Co,...